F10 and COVID-19: Dabigatran was associated with lower odds of COVID-19 death (OR=0.80, 95% CI 0.71 to 0.91) and hospitalisation (OR=0.88, 95% CI 0.79 to 0.98) compared with factor Xa inhibitors (see online supplemental figure 5).